Literature DB >> 19326367

Using short-term response information to facilitate adaptive randomization for survival clinical trials.

Xuelin Huang1, Jing Ning, Yisheng Li, Elihu Estey, Jean-Pierre Issa, Donald A Berry.   

Abstract

Increased survival is a common goal of cancer clinical trials. Owing to the long periods of observation and follow-up to assess patient survival outcome, it is difficult to use outcome-adaptive randomization in these trials. In practice, often information about a short-term response is quickly available during or shortly after treatment, and this short-term response is a good predictor for long-term survival. For example, complete remission of leukemia can be achieved and measured after a few cycles of treatment. It is a short-term response that is desirable for prolonging survival. We propose a new design for survival trials when such short-term response information is available. We use the short-term information to 'speed up' the adaptation of the randomization procedure. We establish a connection between the short-term response and the long-term survival through a Bayesian model, first by using prior clinical information, and then by dynamically updating the model according to information accumulated in the ongoing trial. Interim monitoring and final decision making are based upon inference on the primary outcome of survival. The new design uses fewer patients, and can more effectively assign patients to the better treatment arms. We demonstrate these properties through simulation studies. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19326367      PMCID: PMC2883264          DOI: 10.1002/sim.3578

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  17 in total

1.  Bayesian adaptive biased-coin designs for clinical trials with normal responses.

Authors:  Anthony C Atkinson; Atanu Biswas
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

2.  Bayesian evaluation of group sequential clinical trial designs.

Authors:  Scott S Emerson; John M Kittelson; Daniel L Gillen
Journal:  Stat Med       Date:  2007-03-30       Impact factor: 2.373

3.  Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

4.  Practical Bayesian guidelines for phase IIB clinical trials.

Authors:  P F Thall; R Simon
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

5.  Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.

Authors:  Julie Francart; Catherine Legrand; Richard Sylvester; Martine Van Glabbeke; Jan P van Meerbeeck; Annie Robert
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

6.  A Bayesian group sequential design for a multiple arm randomized clinical trial.

Authors:  G L Rosner; D A Berry
Journal:  Stat Med       Date:  1995-02-28       Impact factor: 2.373

7.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

8.  Continuous Bayesian adaptive randomization based on event times with covariates.

Authors:  Ying Kuen Cheung; Lurdes Y T Inoue; J Kyle Wathen; Peter F Thall
Journal:  Stat Med       Date:  2006-01-15       Impact factor: 2.373

Review 9.  Bayesian clinical trials.

Authors:  Donald A Berry
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

10.  Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.

Authors:  Victor A Levin; Sandra Ictech; Kenneth R Hess
Journal:  BMC Cancer       Date:  2007-06-22       Impact factor: 4.430

View more
  13 in total

1.  Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.

Authors:  Tze L Lai; Philip W Lavori
Journal:  Stat Biosci       Date:  2011-12

2.  Sequential design of phase II-III cancer trials.

Authors:  Tze Leung Lai; Philip W Lavori; Mei-Chiung Shih
Journal:  Stat Med       Date:  2012-03-16       Impact factor: 2.373

3.  Adaptive clinical trial designs in oncology.

Authors:  Yong Zang; J Jack Lee
Journal:  Chin Clin Oncol       Date:  2014-12

4.  A surrogate-primary replacement algorithm for response-adaptive randomization in stroke clinical trials.

Authors:  Amy S Nowacki; Wenle Zhao; Yuko Y Palesch
Journal:  Stat Methods Med Res       Date:  2015-01-12       Impact factor: 3.021

5.  Response adaptive randomization procedures in seamless phase II/III clinical trials.

Authors:  Hongjian Zhu; Jin Piao; J Jack Lee; Feifang Hu; Lixin Zhang
Journal:  J Biopharm Stat       Date:  2019-08-27       Impact factor: 1.051

6.  A novel evaluation of optimality for randomized controlled trials.

Authors:  Jo Wick; Scott M Berry; Hung-Wen Yeh; Won Choi; Christina M Pacheco; Christine Daley; Byron J Gajewski
Journal:  J Biopharm Stat       Date:  2016-06-13       Impact factor: 1.051

7.  Adaptive adjustment of the randomization ratio using historical control data.

Authors:  Brian P Hobbs; Bradley P Carlin; Daniel J Sargent
Journal:  Clin Trials       Date:  2013       Impact factor: 2.486

8.  Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs.

Authors:  Mi-Ok Kim; Chunyan Liu; Feifang Hu; J Jack Lee
Journal:  Stat Med       Date:  2014-05-29       Impact factor: 2.373

Review 9.  Clinical trial designs incorporating predictive biomarkers.

Authors:  Lindsay A Renfro; Himel Mallick; Ming-Wen An; Daniel J Sargent; Sumithra J Mandrekar
Journal:  Cancer Treat Rev       Date:  2016-01-05       Impact factor: 12.111

10.  Evaluating many treatments and biomarkers in oncology: a new design.

Authors:  Richard Kaplan; Timothy Maughan; Angela Crook; David Fisher; Richard Wilson; Louise Brown; Mahesh Parmar
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.